CRSP

CRISPR THERAPEUTICS AG

CRSP·H17182108·US·Common Stock·Healthcare - Biotechnology-13D/G

CRSP (CRISPR THERAPEUTICS AG) is held by 166 institutional investors as of Q1 2026. Largest holders: ARK Investment Management LLC ($538.2M), BlackRock, Inc. ($365.3M), Orbis Allan Gray Ltd ($290.5M). Net institutional sentiment: Mixed.

166
Holders
(17 Elite)
$3B
Total Value
63% (172)
Consensus
108 buying - 64 selling
13F: Insider & Congress:
CRSPSmart Money Verdict
View all
Held by 166 funds
17 elite
Who's Trading
ActivistOIORBIS INVESTMENT MANAGEMENT LTD6.3%May 15, 2026
ActivistCapital World InvestorsCapital World Investors5.1%May 14, 2026
ActivistARK Investment Management LLCARK Investment Management LLC11.8%Apr 30, 2026
InsiderKSKulkarni SamarthSell $469KMar 23, 2026
InsiderKRKASINGER JAMES R.Sell $149KMar 23, 2026
InsiderPRPrasad RajuSell $173KMar 23, 2026
InsiderKSKulkarni SamarthSell $499KMar 16, 2026
InsiderKRKASINGER JAMES R.Sell $166KMar 16, 2026
InsiderPRPrasad RajuSell $282KMar 16, 2026
CongressRJRobert F Kennedy JrSale $1,001 - $15,000Apr 4, 2025
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Increased
11.3M(+7.5%)$538.2M4.2%-16.08%
62
Increased
7.7M(+2.3%)$365.3M0.0%+13.16%
32
Increased
6.1M(+2.6%)$290.5M1.2%+2.03%
50
New
4.7M$224.8M0.0%-8.11%
42
Increased
4M(+6.1%)$189.4M0.0%-5.22%
32
Increased
2.4M(+5.7%)$113.1M0.0%-1.62%
32
Increased
2M(+0.0%)$93M0.0%+36.22%
30
Decreased
1.9M(-5.3%)$88.2M0.1%-16.74%
0
Decreased
1.9M(-5.3%)$88.2M1.2%-6.25%
0
Decreased
1.8M(-30.2%)$83.8M0.0%+17.04%
0
Increased
1.5M(+215.1%)$70.5M0.1%+1.45%
48
Decreased
1.2M(-79.9%)$56.5M0.0%-21.00%
0
New
1.1M$54.4M0.0%-8.11%
41
Increased
1M(+0.9%)$49.4M0.0%-9.83%
29
Decreased
983,072(-10.4%)$46.8M0.0%+37.41%
0
Increased
968,135(+7.7%)$46.1M0.1%-53.95%
32
Increased
802,181(+6.2%)$38.2M0.0%+2.86%
31
Increased
668,142(+0.2%)$31.8M0.0%-5.23%
29
Decreased
593,406(-30.5%)$28.2M0.0%+7.24%
0
New
546,826$26M0.0%-8.11%
40

Showing 1-20 of 177

1 / 9

Other Healthcare stocks held by institutions

Data sourced from four SEC data sources: 13F, Form 4, 13D/13G, and STOCK Act. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used